cisplatin / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

206 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT03734952: Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

Recruiting
N/A
537
RoW
Neoadjuvant Radiotherapy Program:, Neoadjuvant chemotherapy Program, Esophagectomy program:, Postoperative radiotherapy program
Fujian Medical University Union Hospital
Radiation Oncology
01/29
01/29
VAPOR, NCT05705687 / 2021-006638-38: Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors

Recruiting
N/A
150
Europe
BEP Protocol, Dose-dense protocol, Early surgery or high-dose chemotherapy, Dose-dense regimen, Early tumor resection or HD-CT
Gustave Roussy, Cancer Campus, Grand Paris, GUSTAVE ROUSSY
Non-Seminomatous Germ Cell Tumor
02/31
02/37
ChiCTR2300070983: Observation and analysis of therapeutic effects of neoadjuvant chemotherapy in muscle-invasive bladder cancer

Not yet recruiting
N/A
90
 
Chemotherapy began 28 days after randomization, with gemcitabine at 1000mg/m^2, intravenous infusion on days 1 and 8, cisplatin at 70mg/m2, and intravenous infusion on days 2. The cycle was conducted every 3 weeks, totaling 4 cycles. Radical cystectomy combined with bilateral lymph node dissection was also performed 28 days after the last chemotherapy. ;Chemotherapy started 28 days after randomization, methotrexate 30mg/m^2, intravenous drip on the first day, vinblastine 3mg/m^2, doxorubicin 30mg/m^2, cisplatin 70 mg/m^2, intravenous drip on the second day, prophylactic application of granulocyte colony-stimulating factor on the third to ninth days, one cycle every two weeks, a total of six cycles. ;Radical cystectomy combined with bilateral pelvic lymph node dissection was performed 28 days after randomization
900TH Hospital of Joint Logistics Support Force; 900TH Hospital of Joint Logistics Support Force, Fujian provincial key clinical specialty construction project (2017ZDZKMN)
bladder cancer
 
 
NCT00683319: Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

Active, not recruiting
N/A
50
Europe
carboplatin, cisplatin, cyclophosphamide, methotrexate, vincristine sulfate, adjuvant therapy, cognitive assessment, magnetic resonance imaging, magnetic resonance spectroscopic imaging, quality-of-life assessment
Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Ototoxicity
03/34
 
NCT03249519: Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer

Recruiting
N/A
999
Europe
Radiation, Radiation therapy, brachytherapy, Interstitial brachytherapy, Cisplatin, Hyperthermia
University of Erlangen-Nürnberg Medical School
Cervical Cancer
12/94
12/99
HyBla_RCT, NCT05397262: Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia

Recruiting
N/A
1000
Europe
Hyperthermia, Thermal therapy or thermotherapy, Radiotherapy, Chemotherapy 5-Fluorouracil, Chemotherapy Cisplatin
University of Erlangen-Nürnberg Medical School
Bladder Cancer
12/98
12/99
 

Download Options